EA027724B1 - Бронхолитическое средство на основе простагландина - Google Patents
Бронхолитическое средство на основе простагландина Download PDFInfo
- Publication number
- EA027724B1 EA027724B1 EA201401178A EA201401178A EA027724B1 EA 027724 B1 EA027724 B1 EA 027724B1 EA 201401178 A EA201401178 A EA 201401178A EA 201401178 A EA201401178 A EA 201401178A EA 027724 B1 EA027724 B1 EA 027724B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dihydroxy
- inhalation
- keto
- obstructive
- drug
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title claims abstract description 14
- 229940124630 bronchodilator Drugs 0.000 title abstract description 13
- 230000001813 broncholytic effect Effects 0.000 title abstract 2
- 150000003180 prostaglandins Chemical class 0.000 title description 3
- 208000006673 asthma Diseases 0.000 claims abstract description 14
- 230000000414 obstructive effect Effects 0.000 claims abstract description 9
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 8
- 206010006451 bronchitis Diseases 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims abstract description 5
- 229940041682 inhalant solution Drugs 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims description 13
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract description 7
- SGMBTYBNUOWYOV-CXZSOYKBSA-N nitroproston Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(=O)OC(CO[N+]([O-])=O)CO[N+]([O-])=O SGMBTYBNUOWYOV-CXZSOYKBSA-N 0.000 abstract description 4
- 230000003182 bronchodilatating effect Effects 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 description 4
- 231100001274 therapeutic index Toxicity 0.000 description 4
- 208000009079 Bronchial Spasm Diseases 0.000 description 3
- 208000014181 Bronchial disease Diseases 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000000644 isotonic solution Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- ASIGVDLTBLZXNC-UHFFFAOYSA-N 1,3-dinitroglycerol Chemical compound [O-][N+](=O)OCC(O)CO[N+]([O-])=O ASIGVDLTBLZXNC-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229940125388 beta agonist Drugs 0.000 description 2
- 239000000168 bronchodilator agent Substances 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 229940123031 Beta adrenoreceptor agonist Drugs 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102100030817 Liver carboxylesterase 1 Human genes 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101710169844 Sesquipedalian-1 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- WXAXNYYAYJKARR-UHFFFAOYSA-N benzene;2-(1,4-dioxan-2-yl)acetic acid Chemical compound C1=CC=CC=C1.OC(=O)CC1COCCO1 WXAXNYYAYJKARR-UHFFFAOYSA-N 0.000 description 1
- TXHIDIHEXDFONW-UHFFFAOYSA-N benzene;propan-2-one Chemical compound CC(C)=O.C1=CC=CC=C1 TXHIDIHEXDFONW-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229960000665 norflurane Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2012116226/15A RU2500397C1 (ru) | 2012-04-24 | 2012-04-24 | Бронхолитическое средство на основе простагландина |
| PCT/RU2013/000163 WO2013162416A1 (ru) | 2012-04-24 | 2013-03-01 | Бронхолитическое средство на основе простагландина |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201401178A1 EA201401178A1 (ru) | 2015-10-30 |
| EA027724B1 true EA027724B1 (ru) | 2017-08-31 |
Family
ID=49446371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201401178A EA027724B1 (ru) | 2012-04-24 | 2013-03-01 | Бронхолитическое средство на основе простагландина |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9408820B2 (enExample) |
| EP (1) | EP2842554B1 (enExample) |
| JP (1) | JP6126204B2 (enExample) |
| CN (1) | CN104470510A (enExample) |
| AU (1) | AU2013253042B2 (enExample) |
| BR (1) | BR112014026610A2 (enExample) |
| CA (1) | CA2871601C (enExample) |
| EA (1) | EA027724B1 (enExample) |
| RU (1) | RU2500397C1 (enExample) |
| WO (1) | WO2013162416A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015359723A1 (en) * | 2014-12-09 | 2017-04-27 | Société des Produits Nestlé S.A. | Uses of bioactive lipids |
| RU2662099C1 (ru) * | 2017-10-16 | 2018-07-23 | Общество с ограниченной ответственностью "Гурус БиоФарм" | Фармацевтические композиции для ингаляций, содержащие нитропростон |
| RU2695068C1 (ru) * | 2018-06-26 | 2019-07-19 | Общество с ограниченной ответственностью "Гурус БиоФарм" | Средство для лечения хронических облитерирующих заболеваний периферических сосудов на основе простагландина |
| CN117924133A (zh) * | 2022-10-17 | 2024-04-26 | 广州楷石医药有限公司 | 一种前列地尔偶联一氧化氮供体药物及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2067094C1 (ru) * | 1993-09-27 | 1996-09-27 | Владимир Виленович Безуглов | 1,3-динитроглицериновые эфиры полиненасыщенных жирных кислот, гидроксипроизводных полиненасыщенных жирных кислот и простагландинов и способы их получения |
| US5625083A (en) * | 1995-06-02 | 1997-04-29 | Bezuglov; Vladimir V. | Dinitroglycerol esters of unsaturated fatty acids and prostaglandins |
-
2012
- 2012-04-24 RU RU2012116226/15A patent/RU2500397C1/ru active
-
2013
- 2013-03-01 JP JP2015508895A patent/JP6126204B2/ja not_active Expired - Fee Related
- 2013-03-01 AU AU2013253042A patent/AU2013253042B2/en not_active Ceased
- 2013-03-01 CN CN201380022111.6A patent/CN104470510A/zh active Pending
- 2013-03-01 CA CA2871601A patent/CA2871601C/en active Active
- 2013-03-01 BR BR112014026610A patent/BR112014026610A2/pt not_active Application Discontinuation
- 2013-03-01 WO PCT/RU2013/000163 patent/WO2013162416A1/ru not_active Ceased
- 2013-03-01 EP EP13781656.7A patent/EP2842554B1/en not_active Not-in-force
- 2013-03-01 US US14/397,092 patent/US9408820B2/en active Active
- 2013-03-01 EA EA201401178A patent/EA027724B1/ru not_active IP Right Cessation
Non-Patent Citations (3)
| Title |
|---|
| GAIL M. GAUVREAU et al. Protective Effects of Inhaled PGE2 on Allergen-induced Airway Responses and Airway Inflammation, American Journal of Respiratory and critical care medicine, 1999, Vol. 159, p. 31-36 * |
| Липин-инструкция по применению, НИФП, Киев, 18.11.1991. Найдено из Интернет: <URL:http://www.ifp.kiev.ua/doc/metoddoc/lipin.htm, с. 1, 2 * |
| СЕРКОВ И.В. и др. Многофункциональные соединения, содержащие органические нитраты, - прототипы гибридных лекарственных препаратов, Успехи химии, 2009, № 78(5), с. 442-465 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EA201401178A1 (ru) | 2015-10-30 |
| BR112014026610A2 (pt) | 2017-07-18 |
| JP2016506359A (ja) | 2016-03-03 |
| US20150141505A1 (en) | 2015-05-21 |
| EP2842554A4 (en) | 2016-01-06 |
| US9408820B2 (en) | 2016-08-09 |
| CN104470510A (zh) | 2015-03-25 |
| WO2013162416A1 (ru) | 2013-10-31 |
| CA2871601A1 (en) | 2013-10-31 |
| AU2013253042B2 (en) | 2017-08-31 |
| AU2013253042A1 (en) | 2014-12-11 |
| CA2871601C (en) | 2020-02-18 |
| RU2012116226A (ru) | 2013-10-27 |
| JP6126204B2 (ja) | 2017-05-10 |
| EP2842554A1 (en) | 2015-03-04 |
| EP2842554B1 (en) | 2018-10-24 |
| RU2500397C1 (ru) | 2013-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH04504726A (ja) | アナフィラキシーの遅反応性物質に対する拮抗薬としてのリポキシンａ↓４およびその誘導体の使用 | |
| RU2500397C1 (ru) | Бронхолитическое средство на основе простагландина | |
| CN102481284A (zh) | 穿心莲内酯化合物用于治疗炎症和气道病症的用途 | |
| WO2021110061A1 (en) | Peptides and their use in the treatment of inflammation | |
| CN102648908B (zh) | 3-甲基-1-苯基-2-吡唑啉-5-酮与龙脑组合物的应用 | |
| JP2017524709A (ja) | 肺線維症の予防又は治療用医薬組成物の調製におけるアルカロイドの応用 | |
| Zhou et al. | A novel strategy for development of glucocorticoids through non-genomic mechanism | |
| US11091511B2 (en) | Panaxdiol-type ginsenoside derivative, preparation method therefor and use thereof | |
| US11672772B2 (en) | Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for mitigation and/or treatment of pneumonitis/pneumonia/pulmonary fibrosis induced by virus infection and/or by chemical or biological agents | |
| TW200800161A (en) | Composition for treating chronic obstructive pulmonary disease | |
| CN105147670B (zh) | 一种化合物在制备治疗慢性阻塞性肺疾病的药物中的应用 | |
| CN102058613B (zh) | 龙葵中抗肿瘤活性成分组合物的用途 | |
| Barker et al. | Retrobulbar block fails to prevent an increase in serum cortisol concentration on emergence from anaesthesia after cataract surgery | |
| CN114099480A (zh) | 一种雾化吸入型虎杖苷溶液及制备方法 | |
| TWI463985B (zh) | 單離自金剛纂之化合物於癌症和／或血小板數量低下之治療用途 | |
| CN105380953B (zh) | 酸浆苦素p在制备治疗慢性阻塞性肺疾病的药物中的应用 | |
| Hunter | 1 NEW DRUGS | |
| CN104119254B (zh) | 7-去氢-穿心莲内酯-17-磺酸-16-羧酸或其盐、制备方法及其制备药物用途 | |
| CN107868088A (zh) | 苯并二氮杂*类氮氧化物 | |
| CN116514895A (zh) | 一种环索奈德类似物、制备方法及其应用 | |
| CN114588134A (zh) | 一种用于预防和辅助治疗呼吸道疾病的中药组合物雾化液和应用 | |
| CN106692976A (zh) | P‑糖蛋白抑制剂Gelucire44/14作为经口服的盐酸小檗碱吸收促进剂的应用 | |
| CN106727453A (zh) | 一种化合物在制备治疗甲状腺机能减退症药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Registration of transfer of a eurasian patent by assignment | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KG TJ TM |